VPA22020/031/001

Supaverm Oral Suspension

| Variation | Summary | Date |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| Vet - F.I.b.2 b) | VRA-R - Vet - F.I.b.2 b) Vet - F.I.b.2 b) - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate | 26/09/25 |
| Vet - F.I.b.2 b) | VRA-R - Vet - F.I.b.2 b) Vet - F.I.b.2 b) - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate | 26/09/25 |
| Vet - G.I.15 z) | VRA-R - Vet - G.I.15 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - G.I.15 z) Safety, Efficacy, Pharmacovigilance changes - Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 | 12/05/25 |
| Vet - G.I.18 | VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 | 16/11/23 |
| Vet - B44(Do not use) | VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, | 26/06/23 |

| re | reagent or intermediate used in the manufacturing process | |
|----|-----------------------------------------------------------|--|
| О | of the active substance; — excipient | |